Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and demonstrates leadership in G4-targeting therapies for areas of high unmet need in oncology
CARLSBAD, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces today that the U.S. Food and Drug Administration (FDA) has cleared the Company's IND application for QN-302, a potential best-in-class small molecule G-Quadruplex (G4)-selective transcription inhibitor. Based on this clearance, the Company plans to initiate the Phase 1 clinical trial in the second half of 2023 and will enroll patients with advanced or metastatic solid tumors.
Michael Poirier, Qualigen's Chairman and CEO, commented, "This is a pivotal milestone for our therapeutics pipeline as it transitions us into a clinical-stage company. The IND clearance for QN-302 brings us closer to our objective of developing best in class treatments that can potentially provide new therapeutic options for patients with advanced or metastatic solid tumors. Our clinical team has worked diligently to prepare for this milestone and is now dedicated to start enrolling patients, anticipated to take place in the second half of 2023."
The proposed Phase 1 trial is a multicenter, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamic study with dose expansion to evaluate safety, tolerability, and antitumor activity of QN-302 in patients with advanced solid tumors that have not responded to or have recurred following treatment with available therapies. The Company anticipates the dosing of at least 24 patients in the Phase 1 trial can be completed in 2024, funded in part by proceeds received by the divestiture of the Company's diagnostics business in July 2023.
About QN-302
QN-302 is a small molecule G-Quadruplex (G4)-selective transcription inhibitor in Phase 1 clinical development for the treatment of G4-expressing solid tumors, such as pancreatic cancer (PDAC), prostate cancer, sarcomas, and others. QN-302 stabilizes G4 complexes prevalent in the promoter region of oncogenes in many tumor types, impeding transcription of G4-containing cancer genes and potentially offering a tumor-agnostic clinical approach to treatment. Orphan Drug Designation (ODD) was granted by the FDA in January of this year for QN-302 for the intended indication of pancreatic cancer.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against "unwinding," help inhibit cancer cell proliferation. The investigational compounds within Qualigen's family of Pan-RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes' proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers.
研究性新药 (IND) 许可 将 Qualigen Therapeutics 从临床前公司过渡到临床阶段的公司,并在肿瘤学需求高度未得到满足的领域的 G4 靶向疗法方面表现出领导地位
加利福尼亚州卡尔斯巴德,2023 年 8 月 1 日(GLOBE NEWSWIRE)— 专注于开发可能被指定为孤儿药的成人和儿科癌症的临床阶段治疗公司 Qualigen Therapeutics, Inc.(纳斯达克股票代码:QLGN)今天宣布,美国食品药品监督管理局(FDA)已批准该公司对潜在同类最佳小分子 G-Farplex(GPlex)的 QN-302 的IND申请 4)-选择性转录抑制剂。根据这一许可,该公司计划在2023年下半年启动1期临床试验,并将招收晚期或转移性实体瘤患者。
Qualigen董事长兼首席执行官Michael Poirier评论说:“这是我们治疗产品线的关键里程碑,因为它使我们转变为临床阶段的公司。QN-302 的 IND 批准使我们更接近开发一流治疗方法的目标,这些疗法有可能为晚期或转移性实体瘤患者提供新的治疗选择。我们的临床团队一直在努力为这一里程碑做准备,现在致力于开始招收患者,预计将于2023年下半年进行。”
拟议的 1 期试验是一项多中心、开放标签、剂量递增、安全性、药代动力学和药效学研究,旨在评估 QN-302 在使用现有疗法治疗后没有反应或复发的晚期实体瘤患者的安全性、耐受性和抗肿瘤活性。该公司预计,第一阶段试验中至少有24名患者的给药可以在2024年完成,部分资金来自于2023年7月剥离公司诊断业务所获得的收益。
关于 QN-302
QN-302 是一种小分子 G-Qualplex (G4) 选择性转录抑制剂,正处于 1 期临床开发阶段,用于治疗表达 G4 的实体瘤,例如胰腺癌 (PDAC)、前列腺癌、肉瘤等。QN-302 稳定了许多肿瘤类型癌基因启动子区域普遍存在的 G4 复合物,阻碍了含有 G4 的癌症基因的转录,并有可能提供一种与肿瘤无关的临床治疗方法。今年 1 月,美国食品药品管理局批准了 QN-302 孤儿药称号 (ODD),用于胰腺癌的预期适应症。
关于 Qualigen Therapeutics
Qualigen Therapeutics, Inc. 是一家临床阶段的治疗公司,专注于开发成人和儿科癌症的治疗方法。我们正在研究的 QN-302 化合物是一种小分子选择性转录抑制剂,对癌细胞中普遍存在的 G4 具有很强的结合亲和力;这种结合可通过稳定 G4 不受 “松开” 的影响,帮助抑制癌细胞的增殖。据信,Qualigen的Pan-RAS癌基因蛋白质-蛋白质相互作用抑制剂小分子家族中的研究化合物可以抑制或阻断突变的RAS基因蛋白与其效应蛋白的结合,从而使来自突变的RAS的蛋白质无法造成进一步的伤害。从理论上讲,这种作用机制可能有效治疗大约四分之一的癌症,包括某些形式的胰腺癌、结直肠癌和肺癌。